A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants
← catalyst calendarNCT07655518 · readout in 129 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
12estimated
Sites
1
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-25 | actual | When the study began enrolling |
| Primary completion | 2026-12-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-27 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Intervention
- Drug: BMS-986521
Primary outcome
what the primary-completion date above is the date OFPercentage occupancy of M4 receptor in the brain
measured Up to approximately 28 hours after last dose
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed